Skip to main content
Clinical Trials/EUCTR2019-004586-41-GB
EUCTR2019-004586-41-GB
Active, not recruiting
Phase 1

Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: A Randomised controlled trial - Dapagliflozin, Exercise Training and physicAl function; the DETA trial

niversity of Leicester0 sites140 target enrollmentAugust 13, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Frailty and the preceding 'pre-frail' state in patients with type 2 Diabetes Mellitus.
Sponsor
niversity of Leicester
Enrollment
140
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 13, 2020
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversity of Leicester

Eligibility Criteria

Inclusion Criteria

  • (i)Men and women
  • (ii)Age 40 to 75 years, inclusive
  • (iii)Diagnosed T2DM, treated by lifestyle management alone or in combination with mono\- or combination therapy with oral glucose\-lowering pharmacological therapies (with exception of pre\-defined exclusion criteria; see below)
  • (iv)HbA1c 6\.5 to 10% (47 to 86 mmol/mol), inclusive
  • (v) Historical evidence of functional limitation or frailty defined as at least one of :
  • a.Impaired physical function or frailty; SPPB score 1 to 10 (inclusive) recorded within the preceding 5 years
  • b.A coding of mild\-to\-moderate frailty based on the Electronic Frailty Index (eFI) within primary care
  • c.V02peak \= 18 ml/kg recorded within the preceding 5 years
  • d. SARC\-F questionnaire score of 4 or more
  • (vi)BMI \= 25 kg/m2 (\= 22\.5 kg/m2 if of Ssouth Asian ethnicity)

Exclusion Criteria

  • (i)Individuals with type 1, gestational or monogenic diabetes mellitus
  • (ii)eGFR \< 60 ml.min\-1 per 1\.73m2 or as per licencing at the point of prescription
  • (iii)Individuals with familial renal glycosuria
  • (iv)Documented or self\-reported cirrhosis
  • (v)Patients with hereditary problems of galactose intolerance, total lactase deficiency or glucose\-galactose malabsorption
  • (vi)Individual with recurrent balanitis, vaginal or urinary tract infections
  • (vii)Current or planned pregnancy, or breast feeding
  • (viii)Females of childbearing age, unwilling to use adequate contraceptive methods during the study period
  • (ix)Currently on SLGT2i, GLP\-1RA, basal\-bolus or premixed insulin therapies
  • (x)Contra\-indications to exercise or SGLT2i therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials